Bruno Bonaz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8071155/publications.pdf

Version: 2024-02-01

95 papers	8,312 citations	81900 39 h-index	54911 84 g-index
106 all docs	106 docs citations	106 times ranked	8756 citing authors

#	Article	IF	Citations
1	Impact of Gastric Electrical Stimulation on Economic Burden of Refractory Vomiting: A French Nationwide Multicentre Study. Clinical Gastroenterology and Hepatology, 2022, 20, 1857-1866.e1.	4.4	10
2	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology, 2021, 160, 99-114.e3.	1.3	913
3	Diseases, Disorders, and Comorbidities of Interoception. Trends in Neurosciences, 2021, 44, 39-51.	8.6	112
4	Therapeutic Potential of Vagus Nerve Stimulation for Inflammatory Bowel Diseases. Frontiers in Neuroscience, 2021, 15, 650971.	2.8	72
5	The Fourth Bioelectronic Medicine Summit â€œTechnology Targeting Molecular Mechanismsâ€: current progress, challenges, and charting the future. Bioelectronic Medicine, 2021, 7, 7.	2.3	5
6	Gastric Electrical Stimulation Reduces Refractory Vomiting in a Randomized Crossover Trial. Gastroenterology, 2020, 158, 506-514.e2.	1.3	94
7	The vagus nerve and the sympathetic nervous system act in concert to modulate immunity. Brain, Behavior, and Immunity, 2020, 84, 6-7.	4.1	3
8	Targeting the cholinergic anti-inflammatory pathway with vagus nerve stimulation in patients with Covid-19?. Bioelectronic Medicine, 2020, 6, 15.	2.3	45
9	The role of nicotinic receptors in SARS-CoV-2 receptor ACE2 expression in intestinal epithelia. Bioelectronic Medicine, 2020, 6, 20.	2.3	5
10	Transcutaneous auricular vagus nerve stimulation for the treatment of irritable bowel syndrome: a pilot, open-label study. Bioelectronics in Medicine, 2020, 3, 5-12.	2.0	13
11	A 12â€month pilot study outcomes of vagus nerve stimulation in Crohn's disease. Neurogastroenterology and Motility, 2020, 32, e13911.	3.0	76
12	Parameters matter: modulating cytokines using nerve stimulation. Bioelectronic Medicine, 2020, 6, 12.	2.3	8
13	Interoceptive Abilities in Inflammatory Bowel Diseases and Irritable Bowel Syndrome. Frontiers in Psychiatry, 2020, 11, 229.	2.6	16
14	Expectations of IBS patients concerning disease and healthcare providers: Results of a prospective survey among members of a French patientsâ€™ association. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 961-967.	1.5	10
15	A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease. Analytica Chimica Acta, 2019, 1067, 63-70.	5.4	44
16	Vagus Nerve Stimulation at the Interface of Brainâ€“Gut Interactions. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a034199.	6.2	67
17	New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases. British Journal of Clinical Pharmacology, 2019, 85, 722-728.	2.4	6
18	DOP050 Influence of disease location on vedolizumab efficacy in inflammatory bowel disease: a real-life multicentre experience. Journal of Crohn's and Colitis, 2018, 12, S065-S066.	1.3	1

#	Article	IF	Citations
19	Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scandinavian Journal of Gastroenterology, 2018, 53, 442-448.	1.5	12
20	The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Frontiers in Neuroscience, 2018, 12, 49.	2.8	712
21	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 892-899.e2.	4.4	80
22	Electroencephalographic correlates of low-frequency vagus nerve stimulation therapy for Crohnâ€™s disease. Clinical Neurophysiology, 2018, 129, 1041-1046.	1.5	29
23	Emotional overactivity in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2018, 30, e13387.	3.0	20
24	P780 Interchangeability by a biosimilar of infliximab: What do patients think?. Journal of Crohn's and Colitis, 2018, 12, S504-S505.	1.3	0
25	Is-there a place for vagus nerve stimulation in inflammatory bowel diseases?. Bioelectronic Medicine, 2018, 4, 4.	2.3	30
26	P507 What is the impact of infliximab metaoptimisation on surgical rates and need-to-change-therapy in real-world practice for severe inflammatory bowel disease?. Journal of Crohn's and Colitis, 2018, 12, S361-S362.	1.3	0
27	The Place of Stress and Emotions in the Irritable Bowel Syndrome. Vitamins and Hormones, 2017, 103, 327-354.	1.7	57
28	VNS for the Treatment of Inflammatory Disorders of the Gastrointestinal Tract. , 2017, , 205-230.		0
29	Vagus nerve stimulation: a new promising therapeutic tool in inflammatory bowel disease. Journal of Internal Medicine, 2017, 282, 46-63.	6.0	124
30	A crosstalk between muscarinic and CRF2 receptors regulates cellular adhesion properties of human colon cancer cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 1246-1259.	4.1	6
31	Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?. Analytical and Bioanalytical Chemistry, 2017, 409, 1195-1205.	3.7	30
32	The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update. Nutrients, 2017, 9, 1268.	4.1	177
33	The Vagus Nerve in the Neuro-Immune Axis: Implications in the Pathology of the Gastrointestinal Tract. Frontiers in Immunology, 2017, 8, 1452.	4.8	222
34	Involvement of CRF2 signaling in enterocyte differentiation. World Journal of Gastroenterology, 2017, 23, 5127.	3.3	14
35	Vagal tone: effects on sensitivity, motility, and inflammation. Neurogastroenterology and Motility, 2016, 28, 455-462.	3.0	91
36	Antiâ€inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation. Journal of Physiology, 2016, 594, 5781-5790.	2.9	334

#	Article	IF	Citations
37	Effectiveness and Safety of Vedolizumab Induction Therapy forÂPatients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1593-1601.e2.	4.4	168
38	Autonomic Dysfunction: A Predictive Factor of Risk to Develop Rheumatoid Arthritis?. EBioMedicine, 2016, 6, 20-21.	6.1	5
39	Chronic vagus nerve stimulation in Crohn's disease: a 6â€month followâ€up pilot study. Neurogastroenterology and Motility, 2016, 28, 948-953.	3.0	368
40	Stress and the Gastrointestinal System. , 2016, , 123-156.		2
41	Brain responses to uncertainty about upcoming rectal discomfort in quiescent Crohn's disease â€“ a <scp>fMRI</scp> study. Neurogastroenterology and Motility, 2016, 28, 1419-1432.	3.0	40
42	Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. Journal of Crohn's and Colitis, 2016, 10, 812-820.	1.3	35
43	Le ventre, miroir de nos angoisses. , 2016, NÂ° 76, 40-46.		0
44	Therapeutic implications of vagus nerve stimulation. Autonomic Neuroscience: Basic and Clinical, 2015, 192, 8-9.	2.8	0
45	Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseases. Autonomic Neuroscience: Basic and Clinical, 2015, 192, 62.	2.8	0
46	Brain-gut-microbiota axis in Parkinson's disease. World Journal of Gastroenterology, 2015, 21, 10609.	3.3	438
47	Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Expertsâ€™ Criteria. Nutrients, 2015, 7, 4966-4977.	4.1	423
48	Long-Term Therapy With Bevacizumab in a Patient With Glanzmannâ€™s Thrombasthenia and Recurrent Digestive Bleeding due to Gastrointestinal Angiodysplastic Lesions. American Journal of Gastroenterology, 2015, 110, 352-353.	0.4	11
49	Uncertainty in anticipation of uncomfortable rectal distension is modulated by the autonomic nervous system â€” A fMRI study in healthy volunteers. NeuroImage, 2015, 107, 10-22.	4.2	47
50	PropriÃ©tÃ©s anti-inflammatoires du nerf vagueÂ: implications thÃ©rapeutiques en gastroentÃ©rologie. HEGEL - HEpato-GastroEntÃ©rologie LibÃ©rale, 2015, NÂ° 3, 173-179.	0.0	0
51	Relationship between Vagal Tone, Cortisol, TNF-Alpha, Epinephrine and Negative Affects in Crohnâ€™s Disease and Irritable Bowel Syndrome. PLoS ONE, 2014, 9, e105328.	2.5	152
52	Renal sarcoid-like granulomatosis during anti-TNF therapy. Kidney International, 2014, 86, 215.	5.2	12
53	Factors associated with pregnancy outcome in antiâ€<scp>TNF</scp> treated women with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2014, 40, 363-373.	3.7	82
54	Long Term Effects of Low Frequency (10ÂHz) Vagus Nerve Stimulation on EEG and Heart Rate Variability in Crohn's Disease: A Case Report. Brain Stimulation, 2014, 7, 914-916.	1.6	35

#	Article	IF	Citations
55	The link between negative affect, vagal tone, and visceral sensitivity in quiescent <scp>C</scp>rohn's disease. Neurogastroenterology and Motility, 2014, 26, 1200-1203.	3.0	24
56	P299 Vagus nerve stimulation in Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, S188-S189.	1.3	1
57	P500 Efficacy and safety of granulocyte, monocyte/macrophage adsorptive apheresis in steroid-dependent active UC with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 12 weeks. Journal of Crohn's and Colitis, 2014, 8, S276.	1.3	0
58	Nauclea latifolia Smith (Rubiaceae) exerts antinociceptive effects in neuropathic pain induced by chronic constriction injury of the sciatic nerve. Journal of Ethnopharmacology, 2014, 151, 445-451.	4.1	21
59	IntÃ©rÃªt de lâ€™hypnose dans la prise en charge du syndrome de lâ€™intestin irritable. HEGEL - HEpato-GastroEntÃ©rologie LibÃ©rale, 2014, NÂ° 4, 432-433.	0.0	0
60	Occurrence of the Synthetic Analgesic Tramadol in an African Medicinal Plant. Angewandte Chemie - International Edition, 2013, 52, 11780-11784.	13.8	34
61	Non-Celiac Gluten Sensitivity: The New Frontier of Gluten Related Disorders. Nutrients, 2013, 5, 3839-3853.	4.1	418
62	Mon cerveau et mon intestin communiquent, parfois malÂ!. Pratique Neurologique - FMC, 2013, 4, 240-257.	0.1	1
63	Uncoupling between the vagal tone and HPA axis in patients with Crohn's disease or irritable bowel syndrome: Relation to stress and inflammation. Autonomic Neuroscience: Basic and Clinical, 2013, 177, 315-316.	2.8	1
64	Vagus nerve stimulation and the cholinergic anti-inflammatory pathway: A potential new therapeutic approach in inflammatory bowel diseases. Autonomic Neuroscience: Basic and Clinical, 2013, 177, 307.	2.8	0
65	Brain-Gut Interactions in Inflammatory Bowel Disease. Gastroenterology, 2013, 144, 36-49.	1.3	512
66	Vagus nerve stimulation: from epilepsy to the cholinergic antiâ€inflammatory pathway. Neurogastroenterology and Motility, 2013, 25, 208-221.	3.0	229
67	CRF2 Signaling Is a Novel Regulator of Cellular Adhesion and Migration in Colorectal Cancer Cells. PLoS ONE, 2013, 8, e79335.	2.5	18
68	Role of Cholinergic Receptors in Colorectal Cancer: Potential Therapeutic Implications of Vagus Nerve Stimulation?. Journal of Cancer Therapy, 2013, 04, 1116-1131.	0.4	14
69	Inflammatory bowel diseases: a dysfunction of brain-gut interactions?. Minerva Gastroenterologica E Dietologica, 2013, 59, 241-59.	2.2	31
70	Anti-inflammatory effect of vagus nerve stimulation in a rat model of inflammatory bowel disease. Autonomic Neuroscience: Basic and Clinical, 2011, 160, 82-89.	2.8	218
71	Enterocytic differentiation is modulated by lipid rafts-dependent assembly of adherens junctions. Experimental Cell Research, 2011, 317, 1422-1436.	2.6	17
72	Abnormal brain microstructure in patients with chronic pancreatitis. Gut, 2011, 60, 1445-1446.	12.1	2

#	Article	IF	Citations
73	Psychological adjustment and autonomic disturbances in inflammatory bowel diseases and irritable bowel syndrome. Psychoneuroendocrinology, 2010, 35, 653-662.	2.7	157
74	Natural history of acute colonic diverticular bleeding: a prospective study in 133 consecutive patients. Alimentary Pharmacology and Therapeutics, 2010, 32, 466-471.	3.7	80
75	Toward a Definition of a Global Psycho-Physiological Criterion of Vulnerability to Relapse in Inflammatory Bowel Diseases. American Journal of Gastroenterology, 2010, 105, 1446-1447.	0.4	3
76	Multifocal polyclonal Epsteinâ€“Barr virus-associated B-cell lymphoproliferative disorder secondary to azathioprine therapy successfully treated with rituximab. Leukemia and Lymphoma, 2010, 51, 174-177.	1.3	4
77	Dynamic Causal Modelling and physiological confounds: A functional MRI study of vagus nerve stimulation. NeuroImage, 2010, 52, 1456-1464.	4.2	53
78	Comment on a Retraction. American Journal of Gastroenterology, 2009, 104, 1334-1334.	0.4	1
79	Urinary leukotriene E4 excretion: A biomarker of inflammatory bowel disease activity. Inflammatory Bowel Diseases, 2008, 14, 769-774.	1.9	38
80	Brain mapping of digestive sensations elicited by cortical electrical stimulations. Neurogastroenterology and Motility, 2008, 20, 588-596.	3.0	37
81	Risk Factors Associated With Small Bowel Adenocarcinoma in Crohn's Disease: A CaseControl Study. American Journal of Gastroenterology, 2008, 103, 1730-1736.	0.4	72
82	The Cholinergic Anti-Inflammatory Pathway and the Gastrointestinal Tract. Gastroenterology, 2007, 133, 1370-1373.	1.3	32
83	Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. Journal of Clinical Investigation, 2007, 117, 33-40.	8.2	294
84	Endogenous expression and in vitro study of CRF-related peptides and CRF receptors in the rat gastric antrum. Peptides, 2006, 27, 1464-1475.	2.4	32
85	Expression and effects of metabotropic CRF₁and CRF₂receptors in rat small intestine. American Journal of Physiology - Renal Physiology, 2005, 288, G1091-G1103.	3.4	52
86	Effect of nor-trimebutine on neuronal activation induced by a noxious stimulus or an acute colonic inflammation in the rat. Life Sciences, 2005, 77, 2927-2941.	4.3	12
87	Neuronal activity and CRF receptor gene transcription in the brains of rats with colitis. American Journal of Physiology - Renal Physiology, 2004, 287, G803-G814.	3.4	26
88	Irritable bowel syndrome: a model of the brain-gut interactions. Medical Science Monitor, 2004, 10, RA55-62.	1.1	96
89	Central Processing of Rectal Pain in Patients With Irritable Bowel Syndrome: An Fmri Study. American Journal of Gastroenterology, 2002, 97, 654-661.	0.4	147
90	Fedotozine, a kappa-opioid agonist, prevents spinal and supra-spinal Fos expression induced by a noxious visceral stimulus in the rat. Neurogastroenterology and Motility, 2000, 12, 135-147.	3.0	37

#	Article	IF	Citations
91	Corticotropin-releasing factor and systemic capsaicin-sensitive afferents are involved in abdominal surgery-induced Fos expression in the paraventricular nucleus of the hypothalamus. Brain Research, 1997, 748, 12-20.	2.2	51
92	Abdominal surgery induces Fos immunoreactivity in the rat brain. Journal of Comparative Neurology, 1994, 349, 212-222.	1.6	59
93	Water-avoidance stress-inducedc-fos expression in the rat brain and stimulation of fecal output: role of corticotropin-releasing factor. Brain Research, 1994, 641, 21-28.	2.2	144
94	Peripheral bombesin induces c-fos protein in the rat brain. Brain Research, 1993, 600, 353-357.	2.2	48
95	The Irritable Bowel Syndrome: How Stress Can Affect the Amygdala Activity and the Brain-Gut Axis. , 0, , .		4